Page last updated: 2024-10-18

glycine and Shock, Septic

glycine has been researched along with Shock, Septic in 18 studies

Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.

Research Excerpts

ExcerptRelevanceReference
" Our previous studies showed that 20-HETE mimetic, N -(20-hydroxyeicosa-5[Z],14[Z]-dienoyl)glycine (5,14-HEDGE), protects against vascular hyporeactivity, hypotension, tachycardia, and arterial inflammation induced by lipopolysaccharide (LPS) in rats."4.12Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock. ( Anugu, RR; Bahceli, O; Falck, JR; Guden, DS; Horat, MF; Malik, KU; Sahan-Firat, S; Sari, AN; Senol, SP; Temiz-Resitoglu, M; Tunctan, B; Yilmaz, DE, 2022)
" LPS-induced pulmonary vascular injury was significantly attenuated in rats with methotrexate-induced leukocytopenia or treated with ONO-5046, a potent granulocyte elastase inhibitor, although ONO-5046 did not inhibit the LPS-induced increase in serum FDP (E)."3.69Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. ( Murakami, K; Okabe, H; Okajima, K; Takatsuki, K; Uchiba, M, 1995)
" The association of hypoglycemia and increased arterial alanine and glycine with elevated plasma glucagon implied impaired gluconeogenesis."3.66Amino acid metabolism in dogs with E. coli bacteremic shock. ( Duff, JH; Groves, AC; Woolf, LI, 1979)
"Human Gram-negative septic shock, frequently seen in intensive care units, is a condition with high mortality."2.41Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. ( Basu, S; Eriksson, M; Eriksson, O; Kiiski, R; Larsson, A; Mattsson, C; Nordgren, A, 2000)
"Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes."2.40Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999)
"Endotoxic shock is a systemic inflammatory response that is associated with an increase in nitric oxide production and a decrease in the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), which may contribute to the fall in blood pressure and vascular reactivity."1.35A 20-hydroxyeicosatetraenoic acid agonist, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats. ( Anjaiah, S; Buharalioglu, CK; Falck, J; Firat, SS; Korkmaz, B; Malik, KU; Roman, RJ; Tunctan, B, 2008)
"[15N]glycine (100mg) was given orally to children (mean age 5."1.32Assessment of whole body protein metabolism in critically ill children: can we use the [15N]glycine single oral dose method? ( Deutz, NE; Forget, PP; Hoos, MB; Jansen, NJ; van Kreel, BK; van Waardenburg, DA; Vos, GD; Wagenmakers, AJ, 2004)
"Mortality associated with endotoxin shock is likely mediated by Kupffer cells, alveolar macrophages, and circulating neutrophils."1.31Dietary glycine blunts lung inflammatory cell influx following acute endotoxin. ( Enomoto, N; Madren, J; Rose, ML; Seabra, V; Thurman, RG; Wheeler, MD; Yamashima, S, 2000)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19903 (16.67)18.7374
1990's5 (27.78)18.2507
2000's9 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (5.56)2.80

Authors

AuthorsStudies
Tunctan, B2
Senol, SP1
Temiz-Resitoglu, M1
Yilmaz, DE1
Guden, DS1
Bahceli, O1
Horat, MF1
Sahan-Firat, S1
Sari, AN1
Falck, JR1
Anugu, RR1
Malik, KU2
Hagiwara, S1
Iwasaka, H1
Togo, K1
Noguchi, T1
Yende, S1
van Waardenburg, DA1
Deutz, NE1
Hoos, MB1
Jansen, NJ1
van Kreel, BK1
Vos, GD1
Wagenmakers, AJ1
Forget, PP1
Li, L1
Bhatia, M1
Zhu, YZ1
Zhu, YC1
Ramnath, RD1
Wang, ZJ1
Anuar, FB1
Whiteman, M1
Salto-Tellez, M1
Moore, PK1
Korkmaz, B1
Buharalioglu, CK1
Firat, SS1
Anjaiah, S1
Falck, J1
Roman, RJ1
Uchiba, M1
Okajima, K1
Murakami, K1
Okabe, H1
Takatsuki, K1
Ikejima, K1
Iimuro, Y1
Forman, DT1
Thurman, RG3
Hattori, K1
Hirano, T1
Ushiyama, C1
Miyajima, H1
Yamakawa, N1
Ebata, T1
Wada, Y1
Ikeda, S1
Yoshino, K2
Tateno, M1
Oshimi, K1
Kayagaki, N1
Yagita, H2
Okumura, K1
Eriksson, M2
Larsson, A2
Saldeen, T1
Mattsson, C2
Wheeler, MD2
Rose, ML2
Yamashima, S1
Enomoto, N2
Seabra, V2
Madren, J1
Basu, S1
Eriksson, O1
Kiiski, R1
Nordgren, A1
Yamada, K1
Sekikawa, K1
Madarame, H1
Nakane, A1
Ikejema, K1
Stacklewitz, RF1
Zhong, Z1
Yin, M1
Schemmer, P1
Rusyn, I1
Bradford, B1
Quasney, MW1
Waterer, GW1
Dahmer, MK1
Turner, D1
Zhang, Q1
Cantor, RM1
Wunderink, RG1
Woolf, LI1
Groves, AC1
Duff, JH1
Ishida, K1
Totsuka, M1
Hayasaka, H1
Agarwal, MK1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock[NCT03783091]Phase 220 participants (Anticipated)Interventional2019-08-05Recruiting
Hydrogen Sulfide as Prognostic Factor[NCT01088490]50 participants (Actual)Observational2010-01-31Completed
Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation[NCT04443673]59 participants (Actual)Interventional2020-06-15Terminated (stopped due to An interim analysis showed no difference in major outcomes (n=35 glycine and n=24 control participants))
Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481]Phase 213 participants (Actual)Interventional2012-03-31Terminated (stopped due to Some of the researchers finished their participation in the study.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.3908
Placebo0.2035

Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.0819
Placebo0.1668

Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.00007
Placebo0.1739

Changes in Clinical Data Scores (Other Than Sputum Production, Dyspnea and Global Symptoms)

"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Cough questionnaire scoreAppetite questionnaire scoreEnergy questionnaire scoreBody weightHeightHeart rateRespiratory rateTemperature
Glycine81.189.184.6101.6100.5103.594.8100.0
Placebo89.1132.1111.5103.6100.598.1109.0100.1

Changes in FEV1, FEF25, and FEFmax

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Forced expiratory volume at first second (FEV1)Forced expiratory flow at 25%FVC (FEF25)Maximal forced expiratory flow (FEFmax, PEFR)
Glycine109.7133.9115.3
Placebo91.483.391.2

Changes in Other Spirometric Variables

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Forced vital capacity (FVC)Forced expiratory flow at 75%FVC (FEF75)
Glycine104.1111.8
Placebo100.6108.9

Changes in Pulse Oximetry, FEV1/FVC, and FEF50.

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Peripheral oxygen saturation (SpO2)FEV1/FVCForced expiratory flow at 50%FVC (FEF50)
Glycine105.2105.2115.5
Placebo98.994.993.1

Changes in Score for Sputum Production, Dyspnea and Global Symptoms

"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Sputum questionnaire scoreDyspnea questionnaire scoreTotal questionnaire score
Glycine82.075.677.7
Placebo102.6103.898.7

Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

,
Interventionlog (percent change) (Mean)
MyeloperoxidaseIL-1IL-4IL-6IL-7IL-8IL-12IL-13G-CSFIFN-gammaMCP-1MIP-1beta
Glycine-0.4361-0.16350.29640.00850.0356-0.14660.3203-0.0561-0.07760.3272-0.08360.0330
Placebo-0.2906-0.03520.14700.22550.0819-0.23640.26030.19530.22720.36390.0472-0.0608

Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

,
Interventionlog (percent change) (Mean)
MyeloperoxidaseIL-1IL-2IL-4IL-5IL-7IL-8IL-10IL-12IL-13IL-17IFN-gammaMCP-1MIP-1betaTNF-alphaGM-CSF
Glycine0.1294-0.09180.0233-0.01610.24980.0611-0.08240.05490.16750.16300.06800.02480.0042-0.03030.0412-0.0538
Placebo0.0669-0.0102-0.02740.05220.13040.13870.05420.00740.06770.09530.11400.06490.26080.09770.1568-0.0822

Reviews

2 reviews available for glycine and Shock, Septic

ArticleYear
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock.
    Expert opinion on investigational drugs, 2000, Volume: 9, Issue:5

    Topics: Animals; Azetidines; Benzylamines; Glycine; Humans; Shock, Septic; Thrombin

2000
Glycine: a new anti-inflammatory immunonutrient.
    Cellular and molecular life sciences : CMLS, 1999, Nov-30, Volume: 56, Issue:9-10

    Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori

1999

Other Studies

16 other studies available for glycine and Shock, Septic

ArticleYear
Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock.
    Journal of cardiovascular pharmacology, 2022, 08-01, Volume: 80, Issue:2

    Topics: Animals; Arteritis; Cell Cycle Proteins; ErbB Receptors; Glycine; Hydroxyeicosatetraenoic Acids; Hyp

2022
A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1.
    Inflammation, 2008, Volume: 31, Issue:4

    Topics: Animals; Glycine; HMGB1 Protein; Interleukin-6; Leukocyte Elastase; Lipopolysaccharides; Lung; Lung

2008
Role of toll-like receptor 4 mutations in gram-negative septic shock.
    Archives of internal medicine, 2002, Nov-25, Volume: 162, Issue:21

    Topics: Aspartic Acid; Confounding Factors, Epidemiologic; Drosophila Proteins; Genetic Predisposition to Di

2002
Assessment of whole body protein metabolism in critically ill children: can we use the [15N]glycine single oral dose method?
    Clinical nutrition (Edinburgh, Scotland), 2004, Volume: 23, Issue:2

    Topics: Child; Child, Preschool; Critical Illness; Female; Glycine; Humans; Infant; Male; Meningococcal Infe

2004
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:9

    Topics: Alkynes; Animals; Extracellular Signal-Regulated MAP Kinases; Glycine; Hydrogen Sulfide; Inflammatio

2005
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:9

    Topics: Alkynes; Animals; Extracellular Signal-Regulated MAP Kinases; Glycine; Hydrogen Sulfide; Inflammatio

2005
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:9

    Topics: Alkynes; Animals; Extracellular Signal-Regulated MAP Kinases; Glycine; Hydrogen Sulfide; Inflammatio

2005
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:9

    Topics: Alkynes; Animals; Extracellular Signal-Regulated MAP Kinases; Glycine; Hydrogen Sulfide; Inflammatio

2005
A 20-hydroxyeicosatetraenoic acid agonist, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats.
    Shock (Augusta, Ga.), 2008, Volume: 30, Issue:3

    Topics: Animals; Blood Pressure; Endotoxins; Glycine; Heart Rate; Hydroxyeicosatetraenoic Acids; Inflammatio

2008
Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats.
    Thrombosis research, 1995, Apr-15, Volume: 78, Issue:2

    Topics: Amino Acid Chloromethyl Ketones; Amino Acid Sequence; Animals; Anticoagulants; Antithrombin III; Cap

1995
A diet containing glycine improves survival in endotoxin shock in the rat.
    The American journal of physiology, 1996, Volume: 271, Issue:1 Pt 1

    Topics: Animal Feed; Animals; Calcium; Cells, Cultured; Disease Models, Animal; Glycine; Ischemia; Kupffer C

1996
A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice.
    Blood, 1997, Jul-15, Volume: 90, Issue:2

    Topics: Animals; Crosses, Genetic; Fas Ligand Protein; Female; Glycine; Graft vs Host Disease; Humans; Hydro

1997
Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
    Thrombosis and haemostasis, 1998, Volume: 80, Issue:6

    Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Creatinine; Diuresis; Drug Evaluation, Preclin

1998
Dietary glycine blunts lung inflammatory cell influx following acute endotoxin.
    American journal of physiology. Lung cellular and molecular physiology, 2000, Volume: 279, Issue:2

    Topics: Acute Disease; Animals; Calcium; Cells, Cultured; Dietary Supplements; Drug Administration Schedule;

2000
Dietary glycine blunts lung inflammatory cell influx following acute endotoxin.
    American journal of physiology. Lung cellular and molecular physiology, 2000, Volume: 279, Issue:2

    Topics: Acute Disease; Animals; Calcium; Cells, Cultured; Dietary Supplements; Drug Administration Schedule;

2000
Dietary glycine blunts lung inflammatory cell influx following acute endotoxin.
    American journal of physiology. Lung cellular and molecular physiology, 2000, Volume: 279, Issue:2

    Topics: Acute Disease; Animals; Calcium; Cells, Cultured; Dietary Supplements; Drug Administration Schedule;

2000
Dietary glycine blunts lung inflammatory cell influx following acute endotoxin.
    American journal of physiology. Lung cellular and molecular physiology, 2000, Volume: 279, Issue:2

    Topics: Acute Disease; Animals; Calcium; Cells, Cultured; Dietary Supplements; Drug Administration Schedule;

2000
Effect of a matrix metalloproteinase inhibitor on host resistance against Listeria monocytogenes infection.
    FEMS immunology and medical microbiology, 2000, Volume: 29, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Colony Count, Microbial; Fas Ligand Protein; Female; Glycine; Hydro

2000
Intracellular adhesion molecule Gly241Arg polymorphism has no impact on ARDS or septic shock in community-acquired pneumonia.
    Chest, 2002, Volume: 121, Issue:3 Suppl

    Topics: Arginine; Community-Acquired Infections; Genetic Predisposition to Disease; Glycine; Humans; Interce

2002
Amino acid metabolism in dogs with E. coli bacteremic shock.
    Surgery, 1979, Volume: 85, Issue:2

    Topics: Alanine; Amino Acids; Animals; Blood Gas Analysis; Blood Pressure; Blood Urea Nitrogen; Dogs; Escher

1979
[Alanine metabolism in the skeletal muscle and plasma in endotoxemia].
    Nihon Geka Gakkai zasshi, 1985, Volume: 86, Issue:4

    Topics: Alanine; Animals; Glycine; Muscles; Proline; Rabbits; Sepsis; Shock, Septic

1985
Neurotransmitting substances and endotoxin respone in relation to hepatic enzyme induction.
    Pathologia et microbiologia, 1974, Volume: 40, Issue:1

    Topics: Aminobutyrates; Animals; Chloromercuribenzoates; Cortisone; Cyproheptadine; Dihydroxyphenylalanine;

1974